drugset

drugset / Trial / NCT01282606

Clinical Trial to Assess Safety of SI-6603 in Patients With Lumbar Disc Herniation

NCT01282606 ↗

Phase 2 Completed 18 enrolled Seikagaku Corporation

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety of SI-6603 in lumbar disc herniation patients.

Timeline

Start: 2007-12
Primary completion: 2012-08
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Condoliase	Protein / enzyme biologic	—	Other

Indications